Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Hutchison China Drug Application Accepted

Thu, 17th Sep 2020 21:35

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - New drug application for surufatinib as a treatment for advanced pancreatic neuroendocrine tumours accepted for review by China National Medical Products Administration. Application supported by data from its Sanet-p phase 3 study in China.

----------

Securities Trust of Scotland PLC - Edinburgh-based investor - Appoints Troy Asset Management Ltd as investment manager with no change to investment objective. Portfolio to be managed by Tomasz Boniek and wider Troy team. Troy to waive management fee for 12 month and make ongoing contribution to cost of secretarial and administration services. Discount control mechanism to be introduced in order to protect shareholders from company trading at discount to net asset value.

----------

FIH Group PLC - Falkland Islands-based conglomerate - Maintains focus on cash management, with cash as at August end GBP14.1 million. Trading has been hurt by Co As lockdown eases, revenue in both businesses steadily recovers but is still well below prior year levels with "significant loss of revenue in both UK businesses" from Covid-19. Not proposing interim dividend after cancelling financial 2020 dividend. "We still expect to record a loss for the financial year, though, before the costs of redundancies, at a lower underlying level than when we reported to shareholders in June." At its AGM, resolution 8 - which relates to "the disapplication of pre-emption rights, to allot equity securities or sell treasury shares for cash without first offering them to existing shareholders, in circumstances other than for a specific acquisition or capital investment" - fails to pass as does not get required 75% of votes. Board to consult with shareholders to understand and seek to address concerns.

----------

Eden Research PLC - biopesticides and plastic-free formulation technology company - Collaborator Eastman Chemical Co gets authorisation to tell Cedroz in France. Cedroz is Eden's bionematicide, targeting free living parasitic worms called nematodes. French regulator also approves its Mevalone biofungicide for use in organic agriculture in France. Mevalone also gets authorisation for use on tale and wine grapes in Serbia through regional distributor K&N Efthymiadis. Mevalone is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.

----------

ADM Energy PLC - natural resources investor with assets in Nigeria - Formerly submits bid with Nigerian Department of Petroleum Resources for marginal field in 2020 marginal field bid round. 57 marginal fields available to participating companies and ADM is participating in the bid round as strategic partner of OilBank International Ltd. "The company expects the bid round to be concluded by the end of Q4 2020 and will update the market in due course."

----------

Dev Clever Holdings PLC - software and technology group based in Tamworth - Signs three-year commercial partnership with mobile pool betting applications provider Low6. Partnership allow for full integration of Low6's 'PubWars' mobile quiz based pool betting app to be integrated with Dev Clever's Engage gamification platform and 'PubPal' service.Partnership to be funded by fee of GBP115,000 paid to Dev Celevr by Low6 plus ongoing revenue share.

----------

Beowulf Mining PLC - miner with projects in Finland, Sweden, and Kosovo - Notes findings of market assessment of Kallak North by Bo Arvidson. Highlights of assessment include that Kallak ore testwork "has produced an exceptionally high-grade magnetite concentrate" at 71.5% iron content plus only "minimal detrimental components". This makes Kallak the market leading high-grade product within all known and planned future producers. CEO Kurt Budge: "Benchmark iron ore prices climbed to around USD130 a dry metric tonne in late August, the highest level since 2014, and with prices set to remain strong for the remainder of the year, now is the time for the Swedish government to give Kallak the 'green light'."

----------

Prairie Mining Ltd - Poland-focused coal development firm - Receives valid application for small oversubscription of 16.1 million shares at AUD0.25 issued price, raising AUD4.0 million or around GBP2.3 million. Prairie to accept all valid application with no scale back.

----------

Cadence Minerals PLC - London-based mineral resources investment company - Notes first set of results from Hastings Technology Metals, its joint venture partner in the Yangibana rare earth project in Western Australia. First nine holes all hit economic mineralisation. Hastings COO Andrew Reid: "These results have exceeded our expectations, which are an excellent first step in defining what appears to be a significant new zone of mineralisation. With this initial shallow program, we have confirmed the presence of broad mineralised widths and extended known extents of Mineral Resources. All the deepest holes confirm mineralisation continues at depth." Cadence owns 30% of Yangibana, while Hastings owns the other 70%.

----------

Galileo Resources PLC - miner with projects in Botswana, Zambia and South Africa - Begins helicopter-borne electromagnetic survey over two of its tenures within its Kalahari Copper Belt project, Botswana. Preliminary results expected by end of October. CEO Colin Bird: "Our initial activities will be two-fold in that we will investigate an area to the northeast which shows good geophysical potential and an area in the midst of a recent discovery. I have no doubt that time will see the Kalahari Copper Belt region emerging as a significant copper producer, since it already hosts two new world class deposits."

----------

Pan African Resources PLC - African-focused gold producer - Remuneration committee recommends restructuring some its long-term incentive schemes in order to simplify and consolidate, improving retention capability. CEO, financial director, and other executives and prescribed officers agree to relinquish share options under current scheme. In lieu of the relinquishment, restricted B class shares in capital of OAR Gold Prop Ltd will be issues in terms of newly established B-share scheme. Pan African owns 49% share capital of PAR Gold.

----------

Highland Gold Mining Ltd - Russian gold miner - Fortiana Holdings Ltd gets regulatory clearance from Russian Federal Antimonopoly Service in connection with its mandatory cash offer for Highland Gold. Fortiana is to acquire 145.8 million shares in Highland Gold from eight shareholders at GBP3.00 each for a total of GBP437.4 million, giving Fortiana a 40% stake in Highland and valuing the whole company at GBP1.09 billion. It has also put forward an offer to acquire all Highland shares at the same price.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
15 Jul 2022 13:20

IN BRIEF: Hutchmed starts phase I trial of HMPL-A83

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins phase I trial of HMPL-A83 for patients with advanced malignant neoplasms, in China. HMPL-A83 is an investigational novel IgG4-type humanized anti-CD47 monoclonal antibody. Malignant neoplasms are cancerous tumours. It has "significant" potential to be used as a combination therapy with Hutchmed's existing portfolio, the firm says.

Read more
13 Jul 2022 09:35

IN BRIEF: Hutchmed presents solid results from lung cancer study

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Presents positive results from the Savannah phase two trial of Hutchmed and AstraZeneca PLC's savolitinib in combination with Astra's osimertinib in epidermal growth factor receptor-mutated non-small cell lung cancer patients.

Read more
6 Jul 2022 10:37

AIM WINNERS & LOSERS: Hutchmed down amid China Covid woes; Parkmead up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
6 Jul 2022 09:25

Hutchmed phase I trial for IMG-007 doses first patient

(Alliance News) - Hutchmed China Ltd on Wednesday announced the first patient has been dosed for its phase I trial for IMG-007.

Read more
1 Jun 2022 10:07

IN BRIEF: Hutchmed China wins cancer drug Tazverik approval in Hainan

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Receives approval for Tazverik from the Health Commission & Medical Products Administration of the Hainan province in China. The approval is for use in the Hainan pilot zone under the Clinically Urgently Needed Imported Drugs scheme, for the treatment of certain patients with epithelioid sarcoma and follicular lymphoma.

Read more
3 May 2022 12:14

LONDON MARKET MIDDAY: Stocks down as aggressive US Fed rate hike looms

(Alliance News) - Stock prices in London were lower at midday on Tuesday following the long bank holiday weekend in the UK, as markets globally prepare for a sharp US interest rate hike and similar moves by other central banks as they struggle to control inflation.

Read more
3 May 2022 11:29

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
3 May 2022 11:25

IN BRIEF: US FDA says Hutchmed's pancreatic drug needs more testing

Hutchmed (China) Ltd - Hong Kong-based biopharmaceuticals - The US Food & Drug Administration has rejected Hutchmed's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA says the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively. Chief Executive Officer & Chief Scientific Officer Weiguo Su comments: "Although this decision from the FDA is disappointing, we remain confident about the clinical value of surufatinib for NET patients and committed to making surufatinib available to patients globally. We look forward to working with the agency to evaluate its feedback."

Read more
3 May 2022 08:57

LONDON MARKET OPEN: BP rises despite taking hit from Rosneft exit

(Alliance News) - Stock prices in London opened lower on Tuesday following the long bank holiday weekend, with BP shares rising as the oil major planned to return cash to shareholders amid calls by some UK politicians for a windfall profit tax on energy companies.

Read more
3 May 2022 07:53

LONDON MARKET PRE-OPEN: BP swings to quarterly loss after Rosneft exit

(Alliance News) - Stock prices in London are seen opening lower on Tuesday, after the long bank holiday weekend in the UK, as concerns rise over aggressive monetary policy tightening by the US Federal Reserve.

Read more
25 Apr 2022 10:45

AIM WINNERS & LOSERS: musicMagpie sells on new platform; Hutchmed down

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
20 Apr 2022 16:05

UK shareholder meetings calendar - next 7 days

Thursday 21 April 
Alliance Trust PLCAGM
Ibstock PLCAGM
Journeo PLCAGM
Relx PLCAGM
STV Group PLCAGM
Ruffer Investment Co LtdEGM re share issue
Friday 22 April 
Bellevue Healthcare Trust PLCAGM
Faron Pharmaceuticals LtdAGM
Murray International Trust PLCAGM
Monday 25 April 
Belluscura PLCAGM
Capital Gearing Trust PLCGM re non pre-emptive share issue
Cloudbreak Discovery PLCGM re Crescita equity drawdown agreement
Hikma Pharmaceuticals PLCAGM
JPMorgan US Smaller Cos Investment Trust PLCAGM
Polymetal International PLCAGM
Symphony International Holdings LtdAGM
Tuesday 26 April 
Aquis Exchange PLCAGM
Elementis PLCAGM
GlobalData PLCAGM
Oriole Resources PLCAGM
RPS Group PLCAGM
SigmaRoc PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Wednesday 27 April 
Drax Group PLCAGM
EP Global Opportunities Trust PLCAGM
Global Invacom Group LtdAGM
Hutchmed (China) LtdAGM
London Stock Exchange Group PLCAGM
McKay Securities PLCGM re Workspace offer
Nichols PLCAGM
Persimmon PLCAGM
Primary Health Properties PLCAGM
VH Global Sustainable Energy Opportunities PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
31 Mar 2022 10:43

IN BRIEF: Hutchmed China named by SEC, might delist Nasdaq shares

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - US Securities & Exchange Commission identifies Hutchmed China under the new Holding Foreign Companies Accountable Act, which identifies public companies who have used auditors from overseas or auditors who are unable to be investigated completely. The new regulation has no impact on business operations, Hutchmed says.

Read more
31 Mar 2022 10:04

Hutchmed China confident after being added to SEC list

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

Read more
11 Mar 2022 11:15

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.